医学
肠神经系统
疾病
帕金森病
失调
胃肠道
病理生理学
微生物群
中枢神经系统
内科学
生物信息学
病理
重症监护医学
神经科学
作者
Delaram Safarpour,Kaveh Sharzehi,Ronald F. Pfeiffer
出处
期刊:Drugs
[Springer Nature]
日期:2022-01-25
卷期号:82 (2): 169-197
被引量:2
标识
DOI:10.1007/s40265-021-01664-1
摘要
There has been exponential growth in the awareness and understanding of gastrointestinal (GI) dysfunction in Parkinson's disease (PD) over the past 3 decades. The clinical features of GI dysfunction in PD have been clearly identified and innovative research has demonstrated the presence of pathology within the enteric nervous system (ENS) in individuals with PD, leading to suggestions that the GI system may be ground zero for the genesis and the portal of entry of PD pathology, which then ascends via the vagus nerve to the central nervous system (CNS). This theory, as well as the more recent recognition of the association of PD with dysbiosis within the gut microbiota, has been the object of intense study and scrutiny. Since most PD medications are absorbed through the GI system, the need for better understanding of changes within the GI tract that may potentially affect the pattern of response to medications has become evident. In this review, current knowledge of the pathophysiology of changes within the GI tract and the gut microbiome of individuals with PD, including changes that occur with progression of the disease, will be addressed. We focus on common clinical GI problems in PD that can arise from different segments of the GI tract. Relevant diagnostic evaluations and treatment options for each of these problems will be reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI